

1. A preventive and therapeutic agent for hepatic cirrhosis or bile duct disappearance syndrome containing a Fas antagonist as its effective component.
2. A preventive and therapeutic agent according to claim 1 wherein said Fas antagonist is a substance which suppresses binding between Fas and Fas ligand.
3. A preventive and therapeutic agent according to claim 1 or 2 wherein said Fas antagonist is a Fas derivative.
4. A preventive and therapeutic agent according to claim 1 or 2 wherein said Fas antagonist is an anti-Fas ligand antibody.
5. A preventive and therapeutic agent according to ~~any one of claims 1 to 4~~ wherein said hepatic cirrhosis is biliary cirrhosis.
6. A preventive and therapeutic agent according to claim 5 wherein said hepatic cirrhosis is primary biliary hepatic cirrhosis.

A 7. A preventive and therapeutic agent according to ~~any one~~
~~of claims 1 to 4~~ wherein said bile duct disappearance syndrome
is bile duct disappearance syndrome caused by an immunological
mechanism.

✓ Sub-B2 8. A method for preventing and treating hepatic cirrhosis
or bile duct disappearance syndrome wherein a Fas antagonist.

9. Use of a Fas antagonist in producing a pharmaceutical for
preventing and/or treating hepatic cirrhosis or bile duct
disappearance syndrome.

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

add B3